Figure 1.

ICT increases tumor infiltrating cytotoxic tumor antigen-specific CD8⁺ T cells. (A) Experimental timeline. CL4xThy1.1 splenocytes were adoptively transferred into BALB/c mice one day prior to AB1-HA tumor inoculation. Mice were treated with ICT (aCTLA-4 and aPD-L1) or PBS when tumors reached 9 to 20 mm² in size. Tumors (Tum) and corresponding draining lymph nodes (DLN) were harvested 7 days post-treatment. (B) Tumor growth curves of mice treated with PBS (black) or ICT (blue). Each line represents an individual animal. Dotted lines indicate days of treatment. (C) Representative FACS plots, and (D) dot plots representing frequencies of CD8⁺Thy1.1⁺ (HA-specific) T cells in DLN and Tum of both treatment groups. (E) Frequency of granzyme B (GrB) expressing CD8⁺Thy1.1⁺ or Thy1.1⁻ T cells. Data in dot plots represented as mean ± SD. Mann-Whitney U tests were used to compare groups; *P ≤ 0.05. Data represents two independent experiments.